#United States #NASDAQ #Salt Lake City #Co-Diagnostics #CODX

Co-Diagnostics Unveils Reverse Stock Split Plan

In a significant announcement made on December 30, 2025, Co-Diagnostics, Inc. (Nasdaq: CODX), a company specialized in molecular diagnostics, declared its intention to implement a reverse stock split of its common shares. This strategic move comes as part of the company's efforts to comply with Nasdaq's minimum bid price requirements.

Understanding the Reverse Stock Split

Co-Diagnostics will execute a reverse stock split at a ratio of 1-for-30, effective at 12:01 AM ET on January 2, 2026. Post-split, shareholders will find their total shares consolidated, meaning that 30 shares they previously held will be combined into a single share. This amendment will not change the par value of the shares.

The decision to pursue this reverse stock split was validated during a special meeting of stockholders held on December 5, 2025, where they approved a split ratio ranging from at least 1-for-2 to a maximum of 1-for-30, with the final ratio to be determined by the Board of Directors. The approval highlighted stockholder support for initiatives aimed at ensuring the company's compliance with listing standards on The Nasdaq Capital Market.

Implications for Shareholders

While reverse stock splits can sometimes raise concerns around share value dilution, Co-Diagnostics' intention is clear: to bolster its stock price and maintain listing on the Nasdaq exchange. The impact of this split applies to all outstanding shares prior to the effective date and will also influence equity incentive plans by reducing the number of available shares.

Additionally, any outstanding stock options and warrants will see a corresponding increase in their respective exercise prices, maintaining the overall value for the company's financial operations. Importantly, fractional shares will not be created as a result of this split; instead, shareholders eligible for fractional shares will have their amounts rounded up to the nearest whole share.

Future Operations and Compliance

The execution of the reverse stock split is not a guaranteed remedy for compliance with Nasdaq's regulations, as outlined in Co-Diagnostics' forward-looking statements. These statements express management’s plans and expectations but also acknowledge the potential risks and uncertainties involved in achieving compliance.

As the company moves forward, any changes in its stock performance will be closely monitored by investors and analysts alike, especially as Co-Diagnostics is also engaged in the development of its proprietary Co-Dx PCR platform, which aims to revolutionize molecular testing capabilities.

Conclusion

Co-Diagnostics, Inc. is taking decisive steps towards maintaining its position in the capital markets. The execution of a reverse stock split illustrates a proactive approach in navigating the complexities of stock value and compliance in a rapidly evolving industry. Investors and stockholders are encouraged to stay informed as the company transitions into this new chapter, all while pursuing innovations in the diagnostic sector and potentially expanding its market reach.

For any queries pertaining to the split or additional company information, shareholders are advised to connect with the company’s transfer agent, VStock Transfer, LLC, or consult their brokerage for guidance. This strategic move aims not only to ensure compliance but also to inspire confidence among current stakeholders and prospective investors in Co-Diagnostics' enduring potential.